Sleep pill may shield brain from Alzheimer's damage

NCT ID NCT06823752

Recruiting now Disease control Sponsor: Woolcock Institute of Medical Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the insomnia medication lemborexant (Dayvigo) can lower blood markers of brain damage in adults aged 40–65 with insomnia. Twenty participants will take the drug or a placebo for two weeks each, then have their blood tested for proteins linked to Alzheimer's disease. The goal is to see if improving sleep with this drug might protect the brain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lemborexant (Dayvigo)
What this could lead to: If successful, this could suggest that treating insomnia with lemborexant may help protect the brain from damage linked to Alzheimer's disease.
What could go wrong: This is a very small, early-phase study with only 20 people and a short 2-week treatment. It measures blood markers, not actual disease prevention, so results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dementia insomnia Pick disease Plaque, Amyloid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSOMNIA

Contacts and locations

Locations

Woolcock Institute of Medical Research
RECRUITING

Macquarie Park, New South Wales, 2113, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.